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Abstract The initial steps in insulin signal transduction occur at 
the plasma membrane and lead to the activation of phospha-
tidylinositide (Ptdlns) 3-kinase and the formation of 
PtdIns(3,4,5,)P3 in the inner leaflet of the plasma membrane 
which is then converted to PtdIns(3,4)P2 by a specific 
phosphatase. Inhibitors of Ptdlns 3-kinase suppress nearly all 
the metabolic actions of insulin indicating that PtdIns(3,4,5)P3 
and/or PtdIns(3,4)P2 are key 'second messengers' for this 
hormone. A major effect of insulin is its ability to stimulate the 
synthesis of glycogen in skeletal muscle. By 'working backwards' 
from glycogen synthesis, we have dissected an insulin-stimulated 
protein kinase cascade which is triggered by the activation of 
Ptdlns 3-kinase. The first enzyme in this cascade is termed 3-
phosphoinositide-dependent protein kinase (PDKl), because it is 
only active in the presence of PtdIns(3,4,5)P3 or PtdIns(3,4)P2. 
PDKl then activates protein kinase B (PKB) which, in turn, 
inactivates glycogen synthase kinase-3 (GSK3), leading to the 
dephosphorylation and activation of glycogen synthase and hence 
to an acceleration of glycogen synthesis. We review the evidence 
which indicates that the phosphorylation of other proteins by 
PKB and GSK3 is likely to mediate many of the intracellular 
actions of insulin. 
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1. Insulin and diabetes 
Diabetes is characterised by the failure to synthesise, secrete 
or respond to insulin and is the third most prevalent disease in 
the Western world, affecting at least 3% of the population of 
Europe and North America and about 100 million worldwide. 
In at least 75% of diabetics, the level of circulating insulin is 
normal, or even above normal, and the disease is caused by 
the major target tissues for insulin (muscle, fat, liver) becom-
ing resistant to this hormone. In order to understand the 
causes of this disease, it is therefore important to elucidate 
the mechanism by which insulin signals to the cell interior. 
However, this apparently simple problem has proved to be 
remarkably difficult to solve. Although Banting and Macleod 
received the Nobel Prize for Medicine in 1923 for the discov-
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ery of insulin, and Fred Sanger and Dorothy Hodgkin were 
awarded the 1958 and 1964 Nobel Prizes for Chemistry for 
elucidating the amino-acid sequence and three-dimensional 
structure of this hormone, respectively, the signalling mecha-
nism has remained elusive for 75 years. 
2. From the insulin receptor to the formation of 
phosphatidylinositide (3,4,5) triphosphate 
A famous cartoon published in 1979 and reproduced in Fig. 
1 nicely summarises the frustrations of investigators who were 
engaged in studying insulin transduction in the late 1970s. 
However, 3 years later a major breakthrough occurred when 
Ron Kahn and his colleagues discovered that the insulin re-
ceptor [1], like the epidermal growth factor receptor [2], was a 
protein tyrosine kinase. The binding of insulin to the ct-sub-
unit of the receptor activates the protein tyrosine kinase asso-
ciated with the (3-subunit which then phosphorylates itself at 
multiple tyrosine residues. Another crucial finding first made 
by Ron Kahn and Morris White during the 1980s and devel-
oped during the 1990s, was that IRS1 (insulin receptor sub-
strate-1) [3] and a close relative IRS2 [4] are key substrates for 
the insulin receptor. IRS1 and IRS2 interact with a particular 
phosphotyrosine residue on the (3-subunit and are then phos-
phorylated by the receptor at many tyrosine residues. This 
allows them the interact with and recruit SH2-domain-con-
taining proteins to the plasma membrane [5]. One of these 
proteins is phosphatidylinositide (Ptdlns) 3-kinase, an enzyme 
that was first described by Lew Cantley [6] and whose phys-
iological role is to convert a minor inositol phospholipid in 
the plasma membrane, termed phosphatidylinositide (Ptdlns) 
4,5 bisphosphate [PtdIns(4,5)P2], to Ptdlns 3,4,5 trisphosphate 
[PtdIns(3,4,5)P3] [7] (Fig. 2). The advent of two relatively 
specific (but structurally dissimilar) inhibitors of Ptdlns 3-kin-
ase, wortmannin [8] and LY 294002 [9], was critical in dem-
onstrating that this enzyme plays an essential role in medi-
ating nearly all the metablic actions of insulin. Thus, evidence 
has been accumulating the PtdIns(3,4,5)P3, or a metabolite 
derived from it, may be long sought after second messenger 
for insulin, raising the question of how this compound exerts 
its effects on cell function. 
3. The stimulation of glycogen synthase by insulin 
Two approaches can be employed to elucidate signal trans-
duction pathways. One way is to start from the receptor at the 
plasma membrane and to work step by step from the outside 
to the inside of the cell, while the second is to select a phys-
iological action of the hormone and then work backwards 
towards the receptor. The latter method was used by Earl 
Sutherland when he discovered that cyclic AMP is the second 
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Fig. 1. Cartoon drawn by Pierre de Metz and published in Trends 
in Biochemical Sciences in 1979 that summarized the lack of prog-
ress in understanding insulin signal transduction at that time. It was 
known that insulin interacted with a specific receptor in the plasma 
membrane, but how this led to the physiological effects of the hor-
mone was obscure. 
messenger that mediates the adrenergic stimulation of glyco-
genolysis [10], and this is the approach that we have adopted. 
The principal metabolic actions of insulin are to stimulate 
the uptake of nutrients (glucose, amino acids, fatty acids) into 
cells, to accelerate the rate at which they are converted to 
storage macromolecules (protein, glycogen, triglycerides) and 
to inhibit the degradation of these macromolecules. The sys-
tem that we selected for analysis 24 years ago was the syn-
thesis of glycogen in mammalian skeletal muscle, which is 
stimulated by insulin within minutes. The reason for this 
choice was that glycogen synthesis was the only system where 
any biochemical information was available. In the early 1960s 
Joe Larner and his colleagues had discovered that glycogen 
synthase, the enzyme which catalyses the last step in the path-
way of glycogen synthesis, was inactivated by phosphoryla-
tion and reactivated by dephosphorylation [11], the third en-
zyme shown to be regulated in this manner. Larner also 
showed that insulin stimulates glycogen synthase by promot-
ing its dephosphorylation [12], the first enzyme whose activity 
was shown to be regulated by this hormone. It was therefore 
already obvious, even in the 1960s, that insulin must exert this 
effect via inhibition of a protein kinase and/or activation of a 
protein phosphatase. Following the identification of cyclic 
AMP-dependent protein kinase (termed PKA) in 1968 [13], 
PKA was shown to phosphorylate glycogen synthase in vitro 
and to decrease its activity [14,15], suggesting that PKA might 
be the target for insulin. However, the level of cyclic AMP 
was unaffected by insulin under conditions where insulin 
stimulated glycogen synthesis [12], which led to a suggestion 
that insulin might exert its effects via a novel second messen-
ger, which antagonised the activation of PKA by cyclic AMP 
[16]. 
We started working on this problem in late 1973 and, with-
in a few months, had discovered that PKA was not only 
protein kinase capable of phosphorylating glycogen synthase. 
We identified another enzyme that phosphorylated a residue 
on glycogen synthase distinct from that phosphorylated by 
PKA [17], a finding which led our laboratory (and several 
others) to purify and characterise novel glycogen synthase 
kinases. Two years later the area had become very confused 
and the number of residues phosphorylated by PKA [18], the 
number of glycogen synthase kinases and their identities, and 
amount of phosphate bound covalently to glycogen synthase 
[19] were all extremely controversial topics. Ed Krebs added 
fuel to the flames by reporting that some proteins which are 
not phosphorylated in their native states become good sub-
strates when they are unfolded and denatured [20], raising the 
possibility that some phosphorylations might be artefacts of 
no physiological relevance! A cartoon drawn by Peter Roach, 
which he presented at the 1976 IUB meeting in Hamburg, 
admirably summarized the situation at the time (Fig. 3). In 
retrospect, it is clear that everybody depicted in the cartoon 
was partially correct and the confusion was caused by the 
unexpected complexity of the system. Glycogen synthase 
was the paradigm for the phenomenon of 'multisite' phos-
phorylation [21]; i.e. the phosphorylation of a protein at mul-
tiple sites by two or more protein kinases. We now know that 
'multisite phosphorylation' is an extremely common phenom-
enon that is used for a variety of purposes, such as signal 
integration. 
The full complexity of the regulation of glycogen synthase 
has only been revealed over the past 10 years. The enzyme is 
phosphorylated at nine serine residues in vivo by a minimum 
of six protein kinases [22,23] (Fig. 4). Phosphorylation of four 
residues, sites 2a, 2b, 3a and 3b, leads to decreases in the 
activity of glycogen synthase, but the effects are cumulative 
so that almost complete inhibition occurs if all four serines are 
phosphorylated [23,24]. Fluctuations in the level of phospho-
rylation of these residues allows the activity of glycogen syn-
thase to respond to the level of muscle glycogen and the con-
tractile state of the tissue, as well as to the hormones 
adrenalin and insulin. 
However, from the standpoint of insulin's action in this 
system, a key discovery was the finding that most of the 
phosphate released from glycogen synthase in response to 
this hormone is removed from the tryptic peptide-containing 
sites 3a and 3b [25]. Since the protein kinase in muscle extracts 
which is most active in phosphorylating these residues is gly-
cogen synthase kinase-3 (GSK3) [26,27], it therefore appeared 
that insulin must either induce a decrease GSK3 activity or 
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Fig. 2. Molecular mechanism by which insulin stimulates the forma-
tion of PtdIns(3,4,5)P3. The insulin binds to the a-subunit of the in-
sulin receptor, activating the protein tyrosine kinase associated with 
the P-subunit. The P-subunit then phosphorylates itself at a number 
of residues, including Tyr-960. The phosphorylation of Tyr-960 trig-
gers an interaction between the receptor and IRS [71], allowing the 
receptor to phosphorylate IRS1/IRS2 at multiple tyrosine residues. 
Particular phosphotyrosine residues in IRS1/IRS2 then interact with 
the p85 subunit of Ptdlns 3-kinase, thereby recruiting the pi 10 cata-
lytic subunit of Ptdlns 3-kinase to the plasma membrane where it 
converts the inositol phospholipid PtdIns(3,4)P2 to PtdIns(3,4,5)P3. 
PI(3,4,5)P3 is subsequently converted to PtdIns(3,4)P2 by a specific 
5'-phosphatase. 
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Fig. 3. Cartoon drawn and presented by Peter Roach in his poster (1976 IUB meeting Hamburg) that summarized the controversy surrounding 
the regulation of glycogen synthase. The participants in the debate are: West, Tom Soderling (then at Vanderbilt University, Nashville, Tennes-
see); South, Joe Larner (University of Virginia, Charlottesville); North East, Ed Krebs (University of Washington, Seattle; who has subse-
quently removed his beard - a dephosphorylation?!) and myself. 
activate the protein phosphatase which dephosphorylates 
these sites. Importantly, these findings implied that inhibition 
of P K A was not, after all, the target for the action of insulin 
on glycogen synthase. 
4. The inhibition of GSK3 by insulin is likely to be mediated by 
protein kinase B 
The discovery that G S K 3 is inhibited by insulin was made 
by investigators studying the mechanism by which insulin 
stimulates fatty acid synthesis and protein synthesis. Bill Ben-
jamin identified a 'multifunctional' protein kinase which phos-
phorylates a number of proteins, including ATP-citrate lyase, 
the enzyme which converts citrate to acetyl Co A. The activity 
of this kinase was found to decrease by 50% when adipocytes 
were stimulated for a few minutes with insulin, and was sub-
sequently identified by Jim Woodget t and Bill Benjamin as the 
a-isoform of GSK3 [28]. Similarly, Chris Proud described a 
protein kinase which phosphorylates eIF2B, a guanine nucleo-
tide exchange factor essential for the initiation of protein syn-
thesis, and found a 70% decrease in its activity when a Chinese 
hamster ovary cell line that overexpresses the insulin receptor 
was stimulated with insulin; this enzyme was identified as the 
P-isoform of GSK3 [29]. Subsequently, the activities of the oc-
and p-isoforms of G S K 3 were both shown to decrease by 
about 40% when rat L6 myotubes (a skeletal muscle cell 
line) [30] or rat skeletal muscle in situ [31] were stimulated 
with insulin (Fig. 5). 
In unstimulated cells, GSK3 is phosphorylated stoichiomet-
rically at one tyrosine (Tyr-279 in GSK3cc, Tyr-216 in 
GSK3P) and the dephosphorylation of this residue leads to 
inactivation [32]. It had therefore been suggested that the in-
hibition of GSK3 by insulin might results from the activation 
of a protein tyrosine phosphatase. However, the inhibition of 
both G S K 3 isoforms by insulin can be reversed by incubation 
with PP2A, a serine/threonine-specific protein phosphatase, 
indicating that inhibition resulted from serine/threonine phos-
phorylation and not from tyrosine dephosphorylation [29,30]. 
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Fig. 4. Glycogen synthase in rabbit skeletal muscle is phospho-
rylated on nine serine residues in vivo. The serine residues are lo-
cated at residues 7 (site 2a), 10 (2a), 640 (3a), 644 (3b), 648 (3c), 
652 (4), 656 (5), 697 (la) and 710 (lb). Abbreviations: PKA, cyclic 
AMP-dependent protein kinase; PhK, phosphorylase kinase; CaM-
K2, calmodulin-dependent protein kinase-2; CK1, casein kinase-1; 
GSK3, glycogen synthase kinase-3; CK2, casein kinase-2. Most of 
the phosphate released from glycogen synthase in response to insu-
lin is removed from the tryptic peptide-containing sites 3a, 3b and 
3c. 
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Fig. 5. The activation of PKB and the inhibition of GSK3 by insulin in L6 myotubes is prevented by inhibitors of Ptdlns 3-kinase, but is unaf-
fected by rapamycin or PD 98059. L6 myotubes were preincubated with 100 nM wortmannin (closed triangles), with 100 nM rapamycin plus 
50 uM PD 98059 (open circles) or with no additions (closed circles), then stimulated with 0.1 |xM insulin for the times indicated. The cells 
were lysed and PKB and GSK3 immunoprecipitated from the lysates and assayed. Similar results have been obtained in rat skeletal muscle in 
vivo [31]. 
This finding was confirmed subsequently by the isolation of 
tryptic phosphopeptides and amino-acid sequencing [33]. 
These studies showed that, in L6 myotubes, insulin induces 
the phosphorylation of Ser-21 in GSK3a and the equivalent 
residue (Ser-9) in GSK3|3, without altering the 32P-labelling of 
the phosphotyrosine-containing tryptic peptide. 
We initially identified two insulin-stimulated protein kinases 
which phosphorylate GSK3a specifically at Ser-21 and 
GSK3P at Ser-9, and which leads to the inactivation of 
both isoforms in vitro [34,35]. One of these enzymes was 
MAP kinase-activated protein kinase-1 (MAPKAP-K1, also 
known as p90rsk), a component of the classical MAP kinase 
cascade, while the other was p70 S6 kinase, the enzyme which 
mediates the phosphorylation of ribosomal protein S6 [36]. S6 
phosphorylation is induced by insulin (and other growth fac-
tors) and has been implicated in stimulating the translation of 
mRNA transcripts which contain a polypyrimidine tract at 
their 5' transcriptional start site; these transcripts mainly en-
code ribosomal proteins and protein synthesis elongation fac-
tors [37]. 
The insulin-induced activation of the MAP kinase cascade, 
and hence the activation of MAPKAP-K1 can be prevented 
by prior exposure of cells to the drug PD 98059 [38] or to 
cyclic AMP-elevating agents (such as 8-bromo cyclic AMP), 
while the activation of p70 S6 kinase can be prevented by the 
immunosuppressant drug rapamycin [36]. We therefore used 
these compounds to determine which of these insulin-stimu-
lated protein kinases mediated the inhibition of GSK3 by 
insulin. Surprisingly, these experiments revealed that neither 
MAPKAP-K1 nor p70 S6 kinase were rate limiting for the 
inhibition of GSK3 by insulin, because the inhibition of 
GSK3 was unaffected when L6 myotubes were incubated in 
the presence of both PD 98059 and rapamycin under condi-
tions which prevented the activation of MAPKAP-K1 and 
p70 S6 kinase [33]. However, the inhibition of GSK3 by in-
sulin was suppressed by wortmannin (Fig. 5) or by LY 294002 
[33], indicating that inactivation was catalysed by a protein 
kinase whose activation by insulin is dependent on PI 3-kinase 
activity. 
We detected an insulin-stimulated protein kinase in extracts 
prepared from L6 myotubes whose activation was unaffected 
by rapamycin or PD 98059, but prevented by wortmannin, 
and which phosphorylated GSK3a at Ser-21 and GSK3(3 at 
Ser-9 [33]. Immunological studies identified this enzyme as the 
a-isoform of a protein kinase whose catalytic domain is most 
similar to PKA and protein kinase C (PKC) and which has 
therefore been termed protein kinase B (PKB) [39] or RAC 
(related to A and C) kinase [40]. It had already been shown 
that PKB was activated by insulin and other growth factors 
and that activation could be prevented by wortmannin or LY 
294002 or by overexpression of a dominant negative mutant 
of Ptdlns 3-kinase [41,42]. Mutation of tyrosine residues in the 
PDGF receptor that (when phosphorylated) bind to Ptdlns 3-
kinase, also prevented the activation of PKBa [41,42]. Fur-
thermore, expression of a constitutively activated form of 
Ptdlns 3-kinase triggered the activation of PKBa [43^-5]. 
PKB is activated by insulin with a half time of about 1 min 
in L6 myotubes [33] (Fig. 5) or rat skeletal muscle [31], max-
imal activation occurring after 5 min. This is consistent with it 
being 'upstream' of GSK3 which is inhibited with a half time 
of 2 min in L6 myotubes (Fig. 5). GSK3 is also inhibited 
when co-transfected with PKB into human embryonic kidney 
293 cells (D.R. Alessi and P. Cohen, unpublished work). 
5. The mechanism of activation of protein kinase B 
The activated form of PKB can be inactivated by PP2A, 
but not by protein tyrosine phosphatases [33,46], suggesting 
that the activation of PKB is triggered by phosphorylation of 
a serine and/or threonine residue(s). We found that the acti-
vation of PKBa in L6 myotubes was accompanied by the 
phosphorylation of two residues, Thr-308 and Ser-473 [47]. 
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Fig. 6. The signal transduction pathway through which PKB and 
GSK3 may mediate many of the metabolic effects of insulin. The 
steps involved in the stimulation of PtdIns(3,4,5)P3 formation by in-
sulin are shown schematically in Fig. 2. Although transfection of 
3T3-L1 adipocytes with a constitutively active form of PKB mimics 
the action of insulin in stimulating the translocation of GLUT4 
from an intracellular compartment to the plasma membrane, 
GLUT4 itself is not thought to be a physiological substrate for 
PKB. 
Thr-308 is located in the 'activation loop ' between subdo-
mains VII and VIII of the kinase catalytic domain, which 
lies nine residues 'upstream' of a conserved Ala-Pro-Glu mo-
tif; i.e. the same position as the activating phosphorylation 
sites found in many other protein kinases, such as M A P kin-
ase. Ser-473 is not located in the catalytic domain but is very 
close to the C-terminus in a Phe-Xaa-Xaa-Phe/Tyr-Ser/Thr-
Phe/Tyr motif that is present in several protein kinases that 
participate in growth factor-stimulated protein kinase cas-
cades, such as M A P K A P - K 1 , p70 S6 kinase and P K C [48]. 
However, the significance of this observation is not yet clear. 
Several lines of evidence indicate that the phosphorylation 
of Thr-308 and Ser-473 are both required for the full activa-
tion of P K B a [47]. First, the mutat ion of either Thr-308 or 
Ser-473 to Asp (to try and mimic the effect of phosphoryla-
tion by introducing a negative charge) increases the basal 
activity of P K B a about 5-fold, but the effects are synergistic, 
so that activation is 18-fold when bo th sites were mutated to 
Asp. Secondly, the phosphorylation of Ser-473'2 ' in vitro 
causes a 5-fold increase in P K B a activity, but activation is 
25-fold when the phosphorylation of Ser-473 is combined with 
the mutat ion of Thr-308 to Asp. These observations indicate 
that the phosphorylation of Thr-308 and Ser-473 act syner-
gistically to generate a high level of P K B a activity in vivo. 
^ The phosphorylation of Ser-473 is catalysed by MAPKAP kin-
ase-2 in vitro, but this protein kinase does not mediate the insulin-
induced phosphorylation of Ser-473 for reasons discussed in [47]. 
P K B which has been partially activated by mutat ion of Thr-
308 to Asp cannot phosphorylate itself at Ser-473. Similarly, 
P K B which has been partially activated by phosphorylation of 
Ser-473 or by mutat ion of Ser-473 to Asp cannot phospho-
rylate itself at Thr-308 [47]. These observations indicate that 
the enzyme(s) which phosphorylates Thr-308 and Ser-473 in 
vivo is unlikely to be P K B itself. 
6. The mechanism of activation of P K B ; identification of a 
PtdIns(3,4,5)P3-dependent protein kinase-1 (PDK1) 
The insulin- or IGF-1-induced phosphorylation of Thr-308 
and Ser-473, like the activation of PKB, is prevented by wort-
mannin, suggesting that the protein kinase(s) responsible for 
phosphorylating P K B might be dependent on PI(3,4,5)P3 for 
activity [47]. We detected an enzyme which phosphorylates 
P K B at Thr-308 (but not Ser-473) and increases its activity 
30-fold in vitro, and purified it about 500000-fold from skel-
etal muscle extracts to near homogeneity [49]. This enzyme is 
only active in the presence of lipid vesicles containing 
PI(3,4,5)P3 or PI(3,4)P2 and has therefore been termed 3-
phosphoinositide-dependent protein kinase-1 (PDK1). P D K 1 
is not inhibited by wortmannin at concentrations 10-fold 
higher than those which inhibit Ptdlns 3-kinase completely 
[49]. Its apparent molecular mass is 67 kDa, and its catalytic 
domain is most similar to the subfamily of protein kinases 
that include P K A and P K B (D. Alessi, unpublished work). 
The concentration of PI(3,4,5)P3 or PI(3,4)P2 required for 
half maximal activation of P D K 1 in vitro is 1-2 u\M and 
activation is stereospecific; only the D-enantiomers are effec-
tive and many other inositol phospholipids have no effect [49]. 
PtdIns(3,4,5)P3 derivatives containing unsaturated fatty acids 
are much more potent activators of P D K 1 than derivatives 
containing saturated fatty acids [49]. Since unsaturated fat-
ty acids discourage tight packing of adjacent phospholipid 
molecules, it is possible that this arrangement allows for 
more efficient interaction between membrane inserted 
PtdIns(3,4,5)P3 and its effectors, perhaps explaining the bio-
logical significance of the unusual fatty acid composition of 
inositol phospholipids (the D-enantiomer of sn-1-stearoyl, 2-
arachidonyl PtdIns(3,4,5)P3 is likely to be the major species 
that is present in vivo). 
The structure of P K B comprises an N-terminal pleckstrin 
homology (PH) domain of about 100 residues, which is fol-
lowed by the catalytic domain and a C-terminal tail. P H do-
mains in other proteins are known to be capable of interacting 
with inositol phospholipids, and we and others found that 
P K B (via its P H domain) bound with micromolar affinity to 
lipid vesicles containing PI(3,4,5)P3 or PI(3,4)P2 , the interac-
tion with PI(4,5)P2 being about 10-fold weaker [50,51]. How-
ever, neither PI(3,4,5)P3 nor PI(3,4)P2 have any effect on the 
activity of P K B a under conditions where these lipids activate 
P D K 1 strongly [49,50]. 
Our results disagree with recent reports from other labora-
tories which claimed that P K B a is activated directly by 
PtdIns(3,4)P2 [51-53]. Contaminat ion of P K B a preparations 
with trace P D K 1 activity might explain this discrepancy; re-
call that P K A was originally discovered as a trace contami-
nant in purified preparations of phosphorylase kinase (one of 
its 'downstream' targets). It has also been reported that P K B a 
is inhibited by PtdIns(3,4,5)P3 [51,53], but none of the four 
PtdIns(3,4,5)P3 derivatives we tested inhibited the basal P K B a 
8 P. Cohen et al.lFEBS Letters 410 (1997) 3-10 
activity at all, while all four were capable of activating PDK1. 
It is possible that the synthetic PtdIns(3,4,5)P3 used in these 
studies contained impurities that inhibited PKBa. 
Although PKBa is not activated directly by PtdIns(3,4,5)P3 
or PtdIns(3,4)P2, the interaction with these lipids may facili-
tate the activation of PKBa by PDK1 and/or the Ser-473 
kinase, either by a conformational change or by recruiting 
PKBa to the plasma membrane. Indeed, we have recently 
demonstrated that transfected PKBa does translocate to the 
plasma membrane in response to IGF-1 in 293 cells [54]. 
However, neither of these mechanisms appear to be essential 
for the activation of PKBa in vivo, because insulin is reported 
to activate a mutant PKB lacking the PH domain at least as 
well as wild-type PKB [54-56]. Recruitment of PKBa to the 
plasma membrane may therefore play a different role. For 
example, it may facilitate the phosphorylation of membrane-
associated substrates. 
With the discovery of PDK1, the two different approaches 
used to dissect the insulin signal transduction pathway (the 
'outside to inside' and 'inside to outside' approaches) have 
finally met one another to produce the outline of a pathway 
that may explain many of the metabolic actions of insulin 
(Fig. 6). PDK1 is likely to be a major target for the insulin 
second messenger PtdIns(3,4,5)P3 and is therefore a landmark 
in our understanding of insulin signal transduction. It remains 
to be seen whether drugs can be developed which activate 
PDK1 (by mimicking PtdIns(3,4,5)P3) and whether such 
drugs will be efficaceous for the treatment of diabetes. 
GSK3 is a multifunctional protein kinase and its inhibition 
is likely to stimulate the dephosphorylation of a number of 
proteins in vivo. In particular, the inhibition of GSK3 appears 
to underlie the dephosphorylation and activation of eIF2B 
and may therefore contribute to the stimulation of protein 
synthesis initiation [29], as well as to the stimulation of gly-
cogen synthesis (Fig. 6). GSK3 is inhibited potently and rel-
atively specifically by millimolar concentrations of lithium 
ions [57] and, consistent with this finding, lithium ions mimic 
the action of insulin in stimulating glycogen synthesis [58]. It 
will be interesting to see if lithium ions also mimic the effect of 
insulin on protein synthesis. Perhaps drugs which inhibit 
GSK3 specifically will mimic a number of the actions of in-
sulin and also prove to be useful in the treatment of diabetes. 
PKB phosphorylates serine residues in proteins and pepti-
des which lie in Arg-Xaa-Arg-Xaa-Xaa-Ser-Hyd motifs, where 
Hyd is a bulky hydrophobic residue (Phe, Leu) [59]. This 
motif is not only found at the serine residues in GSK3a 
and GSK3P whose phosphorylation is induced by insulin, 
but also surrounding the serines whose phosphorylation 
underlies the activation of 6-phosphofructo-2-kinase (PFK2) 
by insulin in cardiac muscle. These serine residues are phos-
phorylated by PKB in vitro, and their phosphorylation in vivo 
is prevented by wortmannin (but resistant to rapamycin and 
PD 98059) [60,61]. PFK2 catalyses the formation of fructose 
2,6,bisphosphate, a key allosteric activator of 6-phosphofruc-
to-1 -kinase, the rate-limiting enzyme in glycolysis. Thus, the 
phosphorylation of PFK2 by PKB may explain how cardiac 
glycolysis is stimulated by insulin (Fig. 6). 
Insulin stimulates glucose uptake into adipose tissue and 
muscle by promoting the translocation of the glucose trans-
porter GLUT4 from an intracellular location to the plasma 
membrane. This effect is prevented by inhibition of Ptdlns 3-
kinase and mimicked by constitutively active forms of Ptdlns 
3-kinase. Transfection of a constitutively active PKB into 
3T3-L1 adipocytes also mimics the effect of insulin by pro-
moting translocation of GLUT4 to the plasma membrane and 
glucose uptake [62]. The PKB-catalysed phosphorylation of 
an (as yet unidentified) protein may therefore underlie the 
stimulation of glucose uptake by insulin (Fig. 6). 
The activation of p70 S6 kinase is not only prevented by 
rapamycin, but also by wortmannin. PKB has been shown to 
induce the activation of p70 S6 kinase in co-transfection ex-
periments [41], suggesting that PKB may also lie on the signal-
ling pathway by which insulin induces the phosphorylation of 
ribosomal protein S6, and hence the translation of certain 
mRNA transcripts [37]. However, PKB does not phospho-
rylate p70 S6 kinase directly and how it triggers this effect 
is unknown. 
PKB is the cellular homologue of v-Akt, a protein encoded 
in the genome of the AKT-8 acute transforming retrovirus 
isolated from a rodent T-cell lymphoma [63] and has therefore 
also been termed c-Akt. It is therefore intriguing that the 
PKBp isoform is overexpressed in 12% of ovarian cancers, 
10% of pancreatic cancers and 3% of breast cancers 
[40,64,65]. It has recently been found that PKB provides a 
survival signal that protects cells from apoptosis induced by 
ultraviolet radiation, by the withdrawal of the survival factor 
insulin-like growth factor-1 from neuronal cells, and by the 
withdrawal of serum factors while myc is being articially ex-
pressed [66-68]. The activation of PKB by gene amplification 
(and other mechanisms) may therefore contribute to the gen-
eration of malignancies that are able to flourish in the absence 
of extracellular survival signals. The development of specific 
inhibitors of PKB isoforms could be efficaceous for the treat-
ment of some cancers. 
7. Concluding remarks and perspective 
The discovery of PDK1, its role in the activation of PKB 
and the realisation that PKB and GSK3 are likely to play 
many key roles in vivo (Fig. 6), represent significant advances 
in our understanding of insulin signal transduction. Neverthe-
less, many important questions still remain to be answered. 
For example, is it PtdIns(3,4,5)P3, PtdIns(3,4)P2 or both of 
these molecules that activates PDK1 in vivo? This informa-
tion is crucial in order to understand the physiological role 
of the 5'-phosphatase which convers PtdIns(3,4,5)P3 to 
PtdIns(3,4)P2. PDK1 presumably activates the PKB|3 and 
PKBy isoforms, but does it activate other protein kinases as 
well? What is the identity of the protein kinase which phos-
phorylates PKBa at Ser-473 in vivo and is this enzyme, like 
PDK1, also activated directly by PtdIns(3,4,5)P3 and/or 
PtdIns(3,4)P2? Ser-473, and the amino-acid sequence sur-
rounding it, is conserved in PKBP but intriguingly, is absent 
in PKBy [69]. How many proteins do PKB and GSK3 phos-
phorylate in vivo and how many of the intracellular actions of 
insulin do these protein kinases really mediate? Although the 
insulin-induced inhibition of GSK3 in skeletal muscle (40%, 
Fig. 5) is, in theory, almost sufficient to account for the ob-
served (2-fold) stimulation of glycogen synthase, it remains 
entirely possible that insulin also induces the activation of 
the glycogen-associated form of protein phosphatase-1 
(PP1G) which is likely to dephosphorylate glycogen synthase 
in skeletal muscle. Indeed, evidence that PP1G may be acti-
vated by insulin has been presented [70]. Finally, it should be 
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admitted that the genetic evidence needed to establish that 
G S K 3 and cardiac P F K 2 are really physiological substrates 
for PKB, and that glycogen synthase and eIF2B are really 
physiological substrates for GSK3 , is still lacking. Drugs 
which inhibit P K B and G S K 3 specifically would be immensely 
valuable in helping to elucidate their physiological roles, in 
addition to having therapeutic potential. 
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